Lineage Cell Therapeutics, Inc. Increase (Decrease) in Restricted Cash
Lineage Cell Therapeutics, Inc. (LCTX) reported Increase (Decrease) in Restricted Cash of $5.10 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2017-08-09
- Lineage Cell Therapeutics, Inc. increase (decrease) in restricted cash for the quarter ending 2017-06-30 was $5.10M.
- Lineage Cell Therapeutics, Inc. increase (decrease) in restricted cash for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- Lineage Cell Therapeutics, Inc. increase (decrease) in restricted cash for the quarter ending 2016-06-30 was -$815.00K.
- Lineage Cell Therapeutics, Inc. increase (decrease) in restricted cash for the quarter ending 2016-03-31 was $815.00K.
| Period end | Increase (Decrease) in Restricted Cash 3 month | Increase (Decrease) in Restricted Cash 6 month |
|---|---|---|
| 2017-06-30 | $5.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $5.10M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-10 | |
| 2016-06-30 | -$815.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $0.00 10-Q · filed 2017-08-09 |
| 2016-03-31 | $815.00K 10-Q · filed 2017-05-10 | |
| 2015-03-31 | $0.00 10-Q · filed 2016-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |